Topic: Tarceva
ZURICH (Reuters) - Roche Holding AG's cancer drug Tarceva nearly doubles the time patients with a distinct type of lung cancer live without their disease getting worse, a late-stage trial showed on Friday.The data will be presented at this year's American Society ...
PK) announced that Tarceva, one of its blockbuster monoclonal cancer drugs, proved to be very effective against a specific form of lung cancer in a China trial. The Phase III trial of Tarceva, called OPTIMA, compared use of Tarceva alone to a ...
Patients whose advanced lung cancers bear the EGFR mutation survive two to three times longer if given initial treatment with Tarceva, a Chinese study suggests. Caicun Zhou, MD, PhD, of Shanghai Pulmonary Hospital at Tongji University in China, compared first-line treatment with ...
MILAN (Reuters) - Roche's experimental drug MetMab and its established product Tarceva showed impressive results in lung cancer trials on Saturday, highlighting how treating the disease is becoming much more focused.Cancer experts meeting Milan said personalized treatment, first seen in breast cancer, ...
Monday Pfizer (PFE) announced that Sutent failed to prolong survival of lung cancer patients when given in combination with Tarceva. The indication Arqule is pursuing is very similar to that pursued by Pfizer, so had the Sutent trial been successful, it would ...
OSI Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the daily pill Tarceva (erlotinib) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four ...
The number one cancer killer, lung cancer, may be more susceptible to treatment when doctors match up targeted drugs to tumors with key genetic traits, a new study finds.. One of the best -- and somewhat surprising -- results came when Nexavar ...
Pfizer Inc. said Thursday it discontinued a late-stage study of the drug candidate figitumumab in patients with late-stage lung cancer, citing a lack of effectiveness.. "This outcome is disappointing to us and to patients with non-small cell lung cancer," said Dr. Mace ...
Pfizer ends study on potential lung cancer drug, committee says it won't meet treatment goal Pfizer Inc. said Thursday it discontinued a late-stage study of the drug candidate figitumumab in patients with late-stage lung cancer, citing a lack of effectiveness.The study compared ...
SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research - International Association for the Study of Lung Cancer) Joint ...
